| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2009 | CA2344086C Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 02/10/2009 | CA2339299C Method of modulating memory effector t-cells and compositions |
| 02/10/2009 | CA2332521C Pharmaceutical composition for treating or preventing sleep disorders |
| 02/10/2009 | CA2331368C Nucleic acid vaccines for prevention of flavivirus infection |
| 02/10/2009 | CA2328396C New substituted amides, their production and their use |
| 02/10/2009 | CA2301907C Treatment of cell-mediated immune diseases |
| 02/10/2009 | CA2294098C Novel thyroid receptor ligands and method |
| 02/10/2009 | CA2292226C Chlorhexidine formulations, new chlorhexidine salts, solutions containing these and their use |
| 02/10/2009 | CA2288601C Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| 02/10/2009 | CA2286671C Method and formulation for treating vascular disease |
| 02/10/2009 | CA2255681C Composition and method for treating herpes simplex |
| 02/10/2009 | CA2217771C O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same |
| 02/10/2009 | CA2211270C Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| 02/10/2009 | CA2208671C Substituted imides as tnf inhibitors |
| 02/10/2009 | CA2186511C Pyrimidinyl derivatives as interleukin inhibitors |
| 02/10/2009 | CA2166318C Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases |
| 02/10/2009 | CA2138558C Use of r-(+)-.alpha.-lipoic acid, r-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae |
| 02/05/2009 | WO2009018551A2 Therapeutic compounds |
| 02/05/2009 | WO2009018549A1 Therapeutic compounds |
| 02/05/2009 | WO2009018547A1 Extended release formulations containing an ion-channel-modulating compound for the prevention of arrhythmias |
| 02/05/2009 | WO2009018514A1 Dosage form and method of use |
| 02/05/2009 | WO2009018505A1 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
| 02/05/2009 | WO2009018490A1 Bi-dentate compounds as kinase inhibitors |
| 02/05/2009 | WO2009018470A1 Use of cranberry extract enriched in total phenols and free essentially free, or substantially free of sugars, acids, sulfur and other contaminants, for periodontal treatment |
| 02/05/2009 | WO2009018466A1 Naphthyridine derivatives as potassium channel modulators |
| 02/05/2009 | WO2009018431A2 Novel synthetic agonists of tlr9 |
| 02/05/2009 | WO2009018405A1 Integrated photoactive agents and uses thereof |
| 02/05/2009 | WO2009018389A1 Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
| 02/05/2009 | WO2009018373A2 Transdermal administration of (2s) - (4e) -n-methyl-5- (3- ( 5-is0pr0p0xypyridin) yl) -4-penten-2-amine |
| 02/05/2009 | WO2009018367A2 Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine |
| 02/05/2009 | WO2009018353A1 Improved method for the synthesis of substituted formylamines and substituted amines |
| 02/05/2009 | WO2009018350A1 Pyrone analog compositions and methods |
| 02/05/2009 | WO2009018344A1 Anticancer agents |
| 02/05/2009 | WO2009018338A2 Phosphorylated pyrone analogs and methods |
| 02/05/2009 | WO2009018326A2 Soluble pyrone analogs methods and compositions |
| 02/05/2009 | WO2009018320A1 Pyrone analog compositions and methods |
| 02/05/2009 | WO2009018233A1 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| 02/05/2009 | WO2009018209A1 ENDOTHELIN SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF PREDICTING β-ADRENERGIC RECEPTOR TARGETING AGENT EFFICACY |
| 02/05/2009 | WO2009018198A1 Endoparasiticidal topical compositions |
| 02/05/2009 | WO2009018195A2 Fly control method |
| 02/05/2009 | WO2009018188A2 Flea control method |
| 02/05/2009 | WO2009018186A2 Fly control method |
| 02/05/2009 | WO2009018185A2 Ectoparasite control method |
| 02/05/2009 | WO2009018169A1 Substituted cyclohexanols |
| 02/05/2009 | WO2009018166A1 Exercise performance and recovery formulations |
| 02/05/2009 | WO2009018163A1 Hypoxia activated prodrugs of anthracyclines |
| 02/05/2009 | WO2009018152A1 Uses of trientine and penicillamine as countermeasures to metal contamination |
| 02/05/2009 | WO2009018106A2 Stereoselective process for preparing purine dioxolane nucleoside derivatives |
| 02/05/2009 | WO2009018084A1 Small molecule inhibitors of rna silencing |
| 02/05/2009 | WO2009018069A2 Mixtures of cyclodextrin derivatives |
| 02/05/2009 | WO2009018065A2 Novel glucokinase activators and methods of using same |
| 02/05/2009 | WO2009018010A1 Methods for the treatment or prevention of hemorrhagic conditions |
| 02/05/2009 | WO2009017954A1 Inhibitors of jak2 kinase |
| 02/05/2009 | WO2009017948A2 Systems, methods and compositions for reduction of injury from radiation exposure |
| 02/05/2009 | WO2009017874A2 Novel curcumin derivatives and their pharmaceutical uses thereof |
| 02/05/2009 | WO2009017863A2 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
| 02/05/2009 | WO2009017848A1 Compounds, compositions, and methods for the treatment of amyloid diseases such as systemic aa amyloidosis |
| 02/05/2009 | WO2009017837A2 Sublingual fentanyl spray |
| 02/05/2009 | WO2009017836A1 Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| 02/05/2009 | WO2009017825A2 Novel lipoxygenase inhibitors as neuroprotective agents |
| 02/05/2009 | WO2009017822A2 Pi3 kinase modulators and methods of use |
| 02/05/2009 | WO2009017819A1 Pyridine compounds for inflammation and immune-related uses |
| 02/05/2009 | WO2009017818A1 Heterocycle-aryl compounds for inflammation and immune-related uses |
| 02/05/2009 | WO2009017815A1 Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss |
| 02/05/2009 | WO2009017813A1 O-desmethyl venlafaxine saccharinate |
| 02/05/2009 | WO2009017812A2 Pharmaceutical composition of candesartan |
| 02/05/2009 | WO2009017802A1 Nitro-fattyacid modulation of type ii diabetes |
| 02/05/2009 | WO2009017795A1 Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers |
| 02/05/2009 | WO2009017777A2 Metabolites and derivatives of ambrisentan |
| 02/05/2009 | WO2009017767A2 Compositions and methods for dermally treating neuropathy with minoxidil |
| 02/05/2009 | WO2009017755A2 Cb1 antagonists and inverse agonists |
| 02/05/2009 | WO2009017705A1 Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging |
| 02/05/2009 | WO2009017664A1 CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 |
| 02/05/2009 | WO2009017625A1 Treatment of depression, phychosis, and anxiety |
| 02/05/2009 | WO2009017624A2 Compositions with enhanced bioavailability and fast acting inhibitor of gastric acid secretion |
| 02/05/2009 | WO2009017456A1 Pharmaceutical composition suitable for adsorption to the cell surface of pathogenic microbes |
| 02/05/2009 | WO2009017455A1 A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| 02/05/2009 | WO2009017454A1 New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| 02/05/2009 | WO2009017453A1 New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| 02/05/2009 | WO2009017452A1 New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate |
| 02/05/2009 | WO2009017394A1 Substituted cc-1065 analogs and their conjugates |
| 02/05/2009 | WO2009017346A1 Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same |
| 02/05/2009 | WO2009017274A1 An agent for differentiating hematopoietic stem cell into natural killer cell comprising yc-1 or il-21 and a method of differentiating hematopoietic stem cell into natural killer cell using thereof |
| 02/05/2009 | WO2009017269A1 A method for differentiating of human embryonic stem cells into the osteoblastic lineage |
| 02/05/2009 | WO2009017259A1 A medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol |
| 02/05/2009 | WO2009017250A1 Methods for producing aripiprazole suspension and freeze-dried formulation |
| 02/05/2009 | WO2009017236A1 Pyridopyrimidin-4-one derivatives |
| 02/05/2009 | WO2009017222A1 Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism |
| 02/05/2009 | WO2009017219A1 Inhibitor of binding of s1p1 |
| 02/05/2009 | WO2009017193A1 Amino-acid-containing medicinal granular preparation highly easy to take |
| 02/05/2009 | WO2009017190A1 Fused bicyclic compound |
| 02/05/2009 | WO2009017098A1 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
| 02/05/2009 | WO2009016855A1 Method of preventing hair loss and method of preventing hair depigmentation |
| 02/05/2009 | WO2009016812A1 Prophylactic and/or therapeutic agent for anemia comprising 2-phenylquinoline-4-carboxylic acid derivative as active ingredient |
| 02/05/2009 | WO2009016663A1 Amphiphilic dextrin conjugates and their use in pharmaceutical formulations as complexing agents for hydrophobic drugs to improve the aqueous solubility and consequently the therapeutic efficacy of the complexed drugs |
| 02/05/2009 | WO2009016647A1 Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent |
| 02/05/2009 | WO2009016632A1 Edible fat composition for enhancing bone strength |
| 02/05/2009 | WO2009016577A2 A pharmaceutical composition comprising atorvastatin and niacin |
| 02/05/2009 | WO2009016565A1 Tricyclic compounds for the treatment of inflammatory disorders |
| 02/05/2009 | WO2009016564A2 2-aza-bicyclo[3.3.0]octane derivatives |